These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22209316)

  • 1. TNFα: activator or inhibitor of regulatory T cells?
    Biton J; Boissier MC; Bessis N
    Joint Bone Spine; 2012 Mar; 79(2):119-23. PubMed ID: 22209316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNFα in the regulation of Treg and Th17 cells in rheumatoid arthritis and other autoimmune inflammatory diseases.
    Bystrom J; Clanchy FI; Taher TE; Mangat P; Jawad AS; Williams RO; Mageed RA
    Cytokine; 2018 Jan; 101():4-13. PubMed ID: 27639923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proinflammatory mediator-induced reversal of CD4+,CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis.
    van Amelsfort JM; van Roon JA; Noordegraaf M; Jacobs KM; Bijlsma JW; Lafeber FP; Taams LS
    Arthritis Rheum; 2007 Mar; 56(3):732-42. PubMed ID: 17328044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis.
    Baldwin HM; Ito-Ihara T; Isaacs JD; Hilkens CM
    Ann Rheum Dis; 2010 Jun; 69(6):1200-7. PubMed ID: 19773288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-TNFα agents curb platelet activation in patients with rheumatoid arthritis.
    Manfredi AA; Baldini M; Camera M; Baldissera E; Brambilla M; Peretti G; Maseri A; Rovere-Querini P; Tremoli E; Sabbadini MG; Maugeri N
    Ann Rheum Dis; 2016 Aug; 75(8):1511-20. PubMed ID: 26819099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory T cells as therapeutic targets in rheumatoid arthritis.
    Esensten JH; Wofsy D; Bluestone JA
    Nat Rev Rheumatol; 2009 Oct; 5(10):560-5. PubMed ID: 19798031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF alpha as a therapeutic target in rheumatoid arthritis.
    Feldmann M; Brennan FM; Elliott M; Katsikis P; Maini RN
    Circ Shock; 1994 Aug; 43(4):179-84. PubMed ID: 7895323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Present importance of direct immunologically based intervention strategies using anticytokines in rheumatoid arthritis].
    Boehme MW; Gao IK
    Z Rheumatol; 1999 Oct; 58(5):251-66. PubMed ID: 10591973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody.
    Fischer JA; Hueber AJ; Wilson S; Galm M; Baum W; Kitson C; Auer J; Lorenz SH; Moelleken J; Bader M; Tissot AC; Tan SL; Seeber S; Schett G
    Arthritis Rheumatol; 2015 Jan; 67(1):51-62. PubMed ID: 25303306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treg cells in rheumatoid arthritis: an update.
    Cooles FA; Isaacs JD; Anderson AE
    Curr Rheumatol Rep; 2013 Sep; 15(9):352. PubMed ID: 23888361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis.
    Shimizu T; Kamata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol Sci; 2019 Sep; 95(3):90-98. PubMed ID: 31362906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy.
    Bayry J; Sibéril S; Triebel F; Tough DF; Kaveri SV
    Drug Discov Today; 2007 Jul; 12(13-14):548-52. PubMed ID: 17631249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis as a mechanism of action of tumor necrosis factor antagonists in rheumatoid arthritis.
    Makrygiannakis D; Catrina AI
    J Rheumatol; 2012 Apr; 39(4):679-85. PubMed ID: 22422498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of autoimmune arthritis treatment strategies on regulatory T-cell dynamics.
    Mijnheer G; Prakken BJ; van Wijk F
    Curr Opin Rheumatol; 2013 Mar; 25(2):260-7. PubMed ID: 23274520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade.
    Heinhuis B; Koenders MI; van Riel PL; van de Loo FA; Dinarello CA; Netea MG; van den Berg WB; Joosten LA
    Ann Rheum Dis; 2011 Apr; 70(4):660-7. PubMed ID: 21187297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How does infliximab work in rheumatoid arthritis?
    Maini RN; Feldmann M
    Arthritis Res; 2002; 4 Suppl 2(Suppl 2):S22-8. PubMed ID: 12110154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological and clinical effects of anti-TNFalpha treatment.
    Valesini G; Iannuccelli C; Marocchi E; Pascoli L; Scalzi V; Di Franco M
    Autoimmun Rev; 2007 Nov; 7(1):35-41. PubMed ID: 17967723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
    Meroni PL; Valesini G
    BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diallyl Trisulfide can induce fibroblast-like synovial apoptosis and has a therapeutic effect on collagen-induced arthritis in mice via blocking NF-κB and Wnt pathways.
    Liang JJ; Li HR; Chen Y; Zhang C; Chen DG; Liang ZC; Shi YQ; Zhang LL; Xin L; Zhao DB
    Int Immunopharmacol; 2019 Jun; 71():132-138. PubMed ID: 30897500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review.
    Davignon JL; Rauwel B; Degboé Y; Constantin A; Boyer JF; Kruglov A; Cantagrel A
    Arthritis Res Ther; 2018 Oct; 20(1):229. PubMed ID: 30314507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.